» Articles » PMID: 20017659

Nanoparticle-based Vaginal Drug Delivery Systems for HIV Prevention

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2009 Dec 19
PMID 20017659
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Importance Of The Field: Several strategies are being investigated for the prevention of heterosexual transmission of HIV. Of these, topical vaginal drug delivery systems, microbicides, are being actively pursued. HIV prevention by means of a topical microbicide has several drug delivery challenges. These challenges include the vaginal mucosal barriers and potential degradation of the drugs in the vaginal lumen due to pH and enzymes present. Also, new drugs being evaluated as microbicides have specific mechanisms of action, which in some cases require drug targeting to a specific site of action. Nanoparticles provide a delivery strategy for targeted or controlled delivery to the vagina which can be applied in the field of HIV prevention.

Areas Covered In The Review: This review summarizes nanoparticulate systems and their use in mucosal delivery to date. The sexual transmission of HIV along with the various targets to prevent transmission are discussed as well as the potential opportunities, challenges and advantages in using a nanoparticle-based approach for microbicidal drug delivery.

What The Reader Will Gain: This review provides a general understanding of vaginal drug delivery, its challenges, and nanoparticulate delivery systems. Additionally, insight will be gained as to the limited existing application of this technology to the field of HIV prevention.

Take Home Message: To date, few studies have been published that exploit nanoparticle-based microbicidal delivery to the vagina. The use of nanoparticles for vaginal drug delivery provides an approach to overcome the existing barriers to success.

Citing Articles

The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.

Faghihkhorasani A, Ahmed H, Mashool N, Alwan M, Assefi M, Hussein Adab A Virol J. 2023; 20(1):222.

PMID: 37789431 PMC: 10548687. DOI: 10.1186/s12985-023-02183-z.


Cutting edge strategies for screening of novel anti-HIV drug candidates against HIV infection: A concise overview of cell based assays.

Gaikwad S, Phatak P, Mukherjee A Heliyon. 2023; 9(5):e16027.

PMID: 37215829 PMC: 10195898. DOI: 10.1016/j.heliyon.2023.e16027.


Box-Behnken Design of Experiments of Polycaprolactone Nanoparticles Loaded with Irinotecan Hydrochloride.

Mahmoud B, McConville C Pharmaceutics. 2023; 15(4).

PMID: 37111756 PMC: 10141202. DOI: 10.3390/pharmaceutics15041271.


Emulsion-Based Multicompartment Vaginal Drug Carriers: From Nanoemulsions to Nanoemulgels.

Smolenski M, Karolewicz B, Golkowska A, Nartowski K, Malolepsza-Jarmolowska K Int J Mol Sci. 2021; 22(12).

PMID: 34208652 PMC: 8233730. DOI: 10.3390/ijms22126455.


Size-dependent biodistribution of thiol-organosilica nanoparticles and F4/80 protein expression in the genital tract of female mice after intravaginal administration.

Awaad A, Nakamura M Histochem Cell Biol. 2021; 155(6):683-698.

PMID: 33656583 DOI: 10.1007/s00418-021-01974-1.